Thank you for your submission. The information will be live within the next 24-48 hours.
AstraZeneca - ADDC Collaboration
The collaboration allows for ADDC members to have direct access to the AstraZeneca's library of compounds.
This collaboration between ADDC and AstraZeneca is aimed at at facilitating efforts by researchers from academia and institutions towards the discovery of novel compounds with potential pharmaceutical application.
Click here for more information
Highlighted Partnerships
Research Collaboration and license agreement |
|
Beactica Therapeutics AB, the Swedish drug discovery company, and University of Dundee, a top-ranked university in the UK for biological sciences, today announced a new research collaboration... |
Research Collaboration and license agreement |
|
The Drug Discovery Unit announces a partnership with Takeda, Japan’s largest pharmaceutical company, to develop possible new therapeutic treatments for tau pathology, an underlying feature in... |
Research collaboration and license agreement |
|
The University of Dundee‘s Drug Discovery Unit (DDU) has announced a multi-million-pound partnership with Korean-based Bukwang Pharmaceutical Company in a bid to develop a new drug treatment for... |
California Institute for Quantitative Biosciences (QB3) |
|
QB3 isa tri-campus organization at UC Berkeley, UC San Francisco, and UC Santa Cruz. QB3 is the University of California’s hub for innovation and entrepreneurship in the life sciences. The... |
Royal Society of Chemistry |
|
Led by Hiroaki Suga (University of Tokyo), RSC Chemical Biology is a gold open access journal, dedicated to publishing exceptionally significant and breakthrough findings of... |
Therapeuitic Areas of Expertise
-
ChoicesPercentage
-
Oncology32.69%
-
Infectious Diseases15.38%
-
Neurological Disorders34.62%
-
Immunology23.08%
-
Metabolic Disorders21.15%
-
Cardiology13.46%
-
Pain7.69%
-
Other11.54%
-
Therapeutic Approaches
-
ChoicesPercentage
-
Small Molecules78.85%
-
Biologics38.46%
-
Biomarkers3.85%
-
Drug Delivery3.85%
-
Stem Cells3.85%
-
Vaccines1.92%
-
Antibodies9.62%
-
Other1.92%
-